Skip to main content
RAPS Convergence 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Invitation Only
Invitation Only
Separate Ticket or Advanced Registration Required
Separate Ticket or Advanced Registration Required
Repeat Solutions Circle
Repeat Solutions Circle

Charles Nnabuife, BPharm, MBA, PMP, RAC

Project Manager, Regulatory Affairs
NA, Canada

Charles Nnabuife is a certified regulatory affairs and project management professional with more than 14 years of progressive experience in the pharmaceutical industry, specializing in quality assurance, regulatory strategy, and project management. With a strong foundation in pharmacy, Charles has provided expert guidance to organizations at all stages of drug and medical device development. Among his notable achievements, he led a cross-functional team that secured FDA approval for a novel antipsychotic drug within a tight timeline, exemplifying his commitment to excellence and impactful project outcomes.
Charles brings a wealth of expertise in orchestrating successful product launches and ensuring thorough quality management system compliance to guarantee product safety and consistency. Widely recognized for his ability to streamline regulatory processes, he consistently reduces time-to-market for new therapies while ensuring full compliance with international standards—distinguishing him as a leader in regulatory affairs and project management.
He holds a Bachelor of Pharmacy from the University of Jos, an MBA in Marketing from ESUT Business School, and a Postgraduate Diploma in Quality Assurance and Regulatory Affairs from the Academy of Applied Pharmaceutical Sciences in Toronto. Charles’s dedication to upholding regulatory standards and ethical practices underpins his efforts to advance access to safe, high-quality medicinal products.
Outside of his professional commitments, Charles enjoys spending time with his family and reading industry literature, which keeps him informed about emerging trends in pharmaceutical regulation and further strengthens his commitment to innovation and continuous improvement in healthcare.

Presentation(s):